Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 1 country.
Bartłomiej PawlikDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0002-8803-1033
Szymon GrabiaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Mazowiecka 15, 92-215 Lodz, Poland.ORCID 0000-0003-0539-5833
Urszula SmyczyńskaDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Mazowiecka 15, 92-215 Lodz, Poland.ORCID 0000-0003-1399-457X
Wojciech FendlerDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, Mazowiecka 15, 92-215 Lodz, Poland.
Izabela DróżdżDepartment of Clinical and Laboratory Genetics, Medical University of Lodz, Pomorska 251, 92-231 Lodz, Poland.ORCID 0000-0003-1956-5063
Ewa LiszewskaLaboratory of Molecular and Cellular Neurobiology, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland.
Jacek JaworskiLaboratory of Molecular and Cellular Neurobiology, International Institute of Molecular and Cell Biology, Trojdena 4, 02-109 Warsaw, Poland.
Katarzyna KotulskaDepartment of Neurology & Epileptology and Pediatric Rehabilitation, The Children's Memorial Health Institute, Dzieci Polskich 20, 04-730 Warsaw, Poland.
Sergiusz JóźwiakThe Children's Memorial Health Institute, Dzieci Polskich 20, 04-730 Warsaw, Poland.ORCID 0000-0003-3350-6326
Wojciech MłynarskiDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0003-2714-5851
Joanna TrelińskaDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, Sporna 36/50, 91-738 Lodz, Poland.ORCID 0000-0003-1484-4274
Medical University of Lodz · PLChildren's Memorial Health Institute · PLInternational Institute of Molecular and Cell Biology · PLMedical University of Warsaw · PL
Funding
Medical University of Lodz 503/1-090-04/503-11-001-19National Science Center 2015/19/B/NZ5/02229
6 · The paper itself
Abstract
The aim of this study was to assess the potential implication of microRNA on tuberous sclerosis (TSC) pathogenesis by performing microRNA profiling on cell lines silencing
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor. · full record | OpenQuestion